Meg Tirrell joined CNBC in April 2014 as a general assignment reporter focusing on biotechnology and pharmaceuticals. She appears on CNBC's Business Day programming, contributes to CNBC.com and is based at the network's global headquarters in Englewood Cliffs, N.J.
Prior to joining CNBC, she led coverage of the biotechnology industry for Bloomberg News. She broke news on proxy fights, mergers and acquisitions, and drug development, and wrote features that illuminate how science and business meet. She also contributed to Bloomberg Television and Bloomberg Businessweek.
She holds a master's degree in journalism from Northwestern University and a bachelor's degree in English and music from Wellesley College.
Follow her on Twitter @megtirrell.
CNBC's Meg Tirrell reports the latest earnings results for AstraZeneca, Bristol-Myers and Celgene.
CNBC's Meg Tirrell reports on a promising new treatment for hemophilia by Biomarin. And Kadmon has a tough first day of trading.
Harlan Waksal, Kadmon CEO, discusses the company's IPO, and says the focus should be on the products in development going forward.
CNBC's Meg Tirrell breaks down GlaxoSmithKline's quarterly results and provides highlights from CEO Andrew Witty comments to CNBC Europe on Brexit.
CNBC's Meg Tirrell and Jane Wells report on Gilead and Las Vegas Sands earnings previews.
CNBC caught up with Biogen CEO George Scangos to discuss where he leaves the big biotech after six years at the helm.
CNBC's Meg Tirrell reports on a new way Zika can be transmitted.
According to the CDC, there is a new form of Zika virus transmission. CNBC's Meg Tirrell reports.
The new potential form of transmission underscores that the more we learn about Zika, the more concerned public health officials become.